8-K: BeiGene's TEVIMBRA Receives FDA Approval for Advanced Esophageal Cancer Treatment

The FDA has approved BeiGene's TEVIMBRA as a monotherapy for adult patients with advanced esophageal squamous cell carcinoma after prior chemotherapy.

Summary

• The U.S. Food and Drug Administration (FDA) has approved TEVIMBRA (tislelizumab-jsgr) for the treatment of adult patients with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) who have previously undergone systemic chemotherapy that did not include a PD-(L)1 inhibitor.
• This approval is based on the RATIONALE 302 trial, which demonstrated a statistically significant and clinically meaningful survival benefit for TEVIMBRA compared to chemotherapy.
• In the trial, the median overall survival (OS) for patients on TEVIMBRA was 8.6 months, compared to 6.3 months for those on chemotherapy.
• TEVIMBRA is expected to be available in the U.S. in the second half of 2024.
• The FDA is also reviewing Biologics License Applications (BLAs) for tislelizumab as a first-line treatment for ESCC and for gastric or gastroesophageal junction adenocarcinoma, with target action dates in July and December 2024, respectively.
• More than 900,000 patients have been prescribed TEVIMBRA globally to date.

Sentiment

Score: 8

Explanation: The document is positive due to the FDA approval of TEVIMBRA and the demonstrated survival benefit in clinical trials. However, the risks associated with immune-mediated adverse reactions temper the overall sentiment slightly.

Positives

• TEVIMBRA demonstrated a statistically significant and clinically meaningful survival benefit compared to chemotherapy in the RATIONALE 302 trial.
• The approval provides a new treatment option for patients with advanced ESCC who have progressed after initial chemotherapy.
• TEVIMBRA has a favorable safety profile compared to chemotherapy.
• The drug has already been approved in Europe for advanced or metastatic ESCC after prior chemotherapy.
• BeiGene has a broad development program for TEVIMBRA with more than 17 registration-enabling clinical trials.

Negatives

• TEVIMBRA can cause immune-mediated adverse reactions, some of which can be severe or fatal.
• Common adverse reactions include increased glucose, decreased hemoglobin, and fatigue.
• The drug has a risk of immune-mediated pneumonitis, colitis, and hepatitis.
• There is a risk of infusion-related reactions.
• The drug can cause fetal harm if administered to a pregnant woman.

Risks

• There are risks of severe and fatal immune-mediated adverse reactions associated with TEVIMBRA.
• The drug has a risk of immune-mediated pneumonitis, colitis, hepatitis, and endocrinopathies.
• There is a risk of infusion-related reactions.
• The drug can cause fetal harm if administered to a pregnant woman.
• The company relies on third parties for drug development, manufacturing, and commercialization.

Future Outlook

BeiGene is committed to bringing TEVIMBRA to more patients globally and sees it as a critical pillar of their solid tumor development program. The company is also awaiting FDA decisions on first-line ESCC and gastric cancer treatments.

Management Comments

• Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeiGene, stated that the FDA approval of TEVIMBRA for patients with ESCC who have previously received chemotherapy, along with its ongoing review for first-line ESCC patients, represents a significant step in their commitment to bringing this therapy to more patients around the world.
• Syma Iqbal, M.D., Associate Professor of Clinical Medicine, highlighted the clinically meaningful survival benefit of TEVIMBRA for patients with previously treated ESCC.

Industry Context

This approval is significant in the oncology space as it provides a new treatment option for a difficult-to-treat cancer. The approval of TEVIMBRA adds to the growing list of immuno-oncology drugs that are changing the landscape of cancer treatment. The ongoing review for first-line treatment could further expand the market for TEVIMBRA.

Comparison to Industry Standards

• The RATIONALE 302 trial results, with a median overall survival of 8.6 months for TEVIMBRA, compare favorably to historical outcomes with chemotherapy in second-line ESCC treatment.
• Keytruda, another PD-1 inhibitor, has shown efficacy in various cancers, but specific head-to-head comparisons in ESCC are limited, making TEVIMBRA's results significant.
• Opdivo, another PD-1 inhibitor, has also been used in ESCC, but the RATIONALE 302 trial provides specific data for TEVIMBRA in this setting.
• The approval of TEVIMBRA in the second-line setting positions it as a competitor to other checkpoint inhibitors and chemotherapy regimens used in this patient population.

Stakeholder Impact

• Shareholders will likely view the FDA approval positively, potentially increasing the company's stock value.
• Patients with advanced ESCC will have a new treatment option that has shown improved survival rates.
• Employees of BeiGene will be involved in the commercialization and further development of TEVIMBRA.
• Healthcare providers will have a new treatment option to offer their patients.

Next Steps

• TEVIMBRA will be made available in the U.S. in the second half of 2024.
• The FDA will continue to review the Biologics License Applications (BLAs) for tislelizumab as a first-line treatment for ESCC and for gastric or gastroesophageal junction adenocarcinoma.
• BeiGene will continue to conduct clinical trials for TEVIMBRA across various tumor types.

Key Dates

Keywords

TEVIMBRA, tislelizumab, esophageal squamous cell carcinoma, ESCC, FDA approval, oncology, immunotherapy, cancer treatment, RATIONALE 302, BeiGene